



## PRESS RELEASE

FOR IMMEDIATE RELEASE

# Invictus Biotechnology acquires IP for MELT3™ delivery platform

### New Singapore patent granted

**Melbourne Victoria (1 March 2018)** –Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has acquired the Intellectual Property Rights associated with the MELT3™ delivery platform and has been granted a new Singapore patent.

The intellectual property rights to the MELT3™ delivery platform (including all registered and pending patent rights) were previously owned by Gordagen Pharmaceuticals Pty. Ltd. (In Liquidation) and were acquired by Invictus Biotechnology on 24 January 2018. The Singapore MELT3™ patent application was granted on 28 February 2018, and patents have been granted in Australia, New Zealand and South Africa.

Invictus Biotechnology's Executive Chairman, Dr. Glenn Tong, said:

“Our hyperlipidaemia drug candidate which has completed Phase Ia clinical studies is protected by these patents and so it is pleasing to see this patent estate grow day by day. The registration of the Singapore patent, together with the already granted Australian patent, will expedite patent registrations in the ASEAN region.”

Invictus Biotechnology is currently preparing for the commercial launch in the US of two evidence-based nutraceuticals, nE1-Heart™ (for the maintenance of heart health) and nE1-Elite™ (for reduction of Delayed Onset Muscle Soreness, improved muscle recovery after exercise and improved



maintenance of muscle peak power). The Company expects to see additional patent registrations in important markets including the US, Japan and China in the next few months and patent applications have been filed in a number of other major markets.

**Investor and Media Enquiries:**

Dr. Douglas Pretsell, Investor and Media Relations  
Ph: +61 (0) 409 908 553

**Corporate enquiries:**

Dr. Glenn Tong, Executive Chairman  
Ph: +61 (0) 412 193 350

---

## About Invictus Biotechnology

Invictus Biotechnology Pty. Ltd. is a private Australian biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, hyperlipidaemia, hypertension and diabetes. Invictus Biotechnology owns and controls patent and other intellectual property rights for novel approaches to delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.